Series of skin-whitening (lightening) compounds

US12227472B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12227472-B2
Application numberUS-202318238905-A
CountryUS
Kind codeB2
Filing dateAug 28, 2023
Priority dateJul 21, 2008
Publication dateFeb 18, 2025
Grant dateFeb 18, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

First claim

Opening claim text (preview).

The invention claimed is: 1. A composition comprising the compound of Formula V: or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from the group consisting of H or C 1 -C 10 alkyl; Bn is a benzyl; and R′ is 1 to 3 moieties (R′, R″, R′″) independently selected from the group consisting of a C 1 -C 10 alkyl group, a C 1 -C 10 alkoxy group or a hydroxyl group; and a pharmaceutically or cosmetically acceptable carrier. 2. A method of producing the compound in claim 1 by utilizing a compound comprising Formula IV as a starter compound or an intermediate compound: wherein represents double or single bond, R 1 is selected from the group consisting of H or C 1 -C 10 alkyl; R 4 is selected from the group consisting of H, OH or O; and R 5 is a selected from the group consisting of a substituted or unsubstituted: aromatic ring, heteroaromatic ring, heterocyclic ring or a hydroxylalkyl moiety. 3. The method of claim 2 , wherein R 1 is H or CH 3 and R 5 is selected from a substituted or unsubstituted: aromatic ring, heteroaromatic ring or a heterocyclic ring or a C 1 -C 10 hydroxylalkyl (—C 1 -C 10 )—OH). 4. The method of claim 2 , wherein R 5 is substituted with 1 to 3 moieties (R′, R″, R′″) independently selected from the group consisting of a C 1 -C 10 alkyl group, a C 1 -C 10 alkoxy group or a hydroxyl group.

Assignees

Inventors

Classifications

  • Aryl or substituted aryl radicals · CPC title

  • attached in position 2 or 6 · CPC title

  • Anti-ageing preparations · CPC title

  • only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455) · CPC title

  • having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12227472B2 cover?
The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.
Who is the assignee on this patent?
Unigen Inc
What technology area does this patent fall under?
Primary CPC classification C07C43/23. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).